No headlines found.
Enliven Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules
PRNewswire (Thu, 11-Dec 4:22 PM ET)
Enliven Therapeutics Announces New CEO to Drive Next Phase of Development
PRNewswire (Thu, 11-Dec 9:00 AM ET)
/C O R R E C T I O N -- Enliven Therapeutics, Inc./
PRNewswire (Wed, 12-Nov 9:56 PM ET)
Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update
PRNewswire (Wed, 12-Nov 4:05 PM ET)
PRNewswire (Mon, 3-Nov 9:06 AM ET)
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
Enliven Therapeutics trades on the NASDAQ stock market under the symbol ELVN.
As of December 24, 2025, ELVN stock price climbed to $16.73 with 332,584 million shares trading.
ELVN has a beta of 0.72, meaning it tends to be less sensitive to market movements. ELVN has a correlation of 0.04 to the broad based SPY ETF.
ELVN has a market cap of $992.88 million. This is considered a Small Cap stock.
The top ETF exchange traded funds that ELVN belongs to (by Net Assets): VTI, IWM, VXF, IWO, IBB.
ELVN has underperformed the market in the last year with a price return of -28.6% while the SPY ETF gained +17.3%. ELVN has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -12.8% and -14.2%, respectively, while the SPY returned +4.4% and +1.4%, respectively.
ELVN support price is $15.67 and resistance is $17.39 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ELVN shares will trade within this expected range on the day.
